Evidence map›Paper›PMID 41188760›Full record

ArticleBMC cancer2025

Effect of chemotherapeutic drugs and cytochalasin B on tunneling nanotubes in U87 MG cells.

Nicole Matejka, Jessica Neubauer, Judith Reindl

Abstract read
In one paragraph

Article in BMC cancer, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Review
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Nicole MatejkaInstitute for Applied Physics and Measurement Technology, University of the Bundeswehr Munich, Neubiberg, Germany. Nicole.matejka@unibw.de.
Jessica NeubauerInstitute for Applied Physics and Measurement Technology, University of the Bundeswehr Munich, Neubiberg, Germany.
Judith ReindlInstitute for Applied Physics and Measurement Technology, University of the Bundeswehr Munich, Neubiberg, Germany.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Intercellular communication in the tumor microenvironment has a major impact on therapeutic outcomes. In particular, highly aggressive cancers such as glioblastoma benefit from efficient cellular communication by developing resistance to therapy or by infiltrating surrounding tissue to escape radiotherapy. Tiny membrane tunnels, such as tunneling nanotubes (TNTs), can serve as an effective communication tool for tumor cells. With these structures, the cells can build a large network that allows them to react and adapt to their environment as quickly as possible, thereby combating the therapy. In this study, we investigated the effects of chemotherapeutic agents on TNT networks in U87 MG cells to determine if they affect the number of TNTs and, consequently, possible therapeutic outcomes. The effect of drugs on TNT stability may be related to their effects on actin and tubulin, which are known stabilizers of membrane structures. Therefore, we also analyzed the cytoskeletal content of TNTs in U87 MG cells and examined the effect of the actin polymerization inhibitor cytochalasin B (CytoB) on TNT formation and networks. CytoB reduced the number of TNTs in this study, suggesting that actin, as a cytoskeletal component, is required for developing TNT networks. In contrast, the chemotherapeutic agents temozolomide (TMZ) and cytarabine (AraC) do not affect TNTs and actin content. As TNT networks are closely linked to increased therapy resistance of certain tumors, we believe that the lack of suppression of TNTs is a major problem in current glioblastoma therapy and should be a target for further research in the future.

Indexed as

Antineoplastic AgentsCell CommunicationCytochalasin BGlioblastomaNanotubesActinsCell Line, TumorCytarabineCytoskeletonHumansTemozolomideActinsAntineoplastic AgentsCytarabineCytochalasin BTemozolomideCellular communicationChemotherapyDrugsGlioblastomaTherapy resistanceTunneling nanotubes

Identifiers

PMID41188760
PMCPMC12587739

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.